Journal Information
Vol. 42. Issue 4.
Pages 194-201 (April 2006)
Share
Share
Download PDF
More article options
Vol. 42. Issue 4.
Pages 194-201 (April 2006)
Review Article
Full text access
Controversies in the Treatment of Extrapulmonary Tuberculosis
Visits
8303
Z.M. Fuentesa, J.A. Caminero*,b
a Servicio de Neumología, Hospital General Dr. José Ignacio Baldó, El Algodonal, Caracas, Venezuela
b Servicio de Neumología, Hospital General de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Tuberculosis (TB) can spread to any tissue or organ of the body by way of hematogenous or lymphatic dissemination or contiguity. However, pulmonary TB is the most common presentation and the only form of the disease of epidemiologic importance. Consequently, the literature on the various forms of extrapulmonary TB (EPTB) is scant, and most of the published authors are specialists in specific extrapulmonary forms. As a result, in most of the major areas of study of EPTB, recommendations similar to those for pulmonary TB or others based on little or no evidence have been accepted. This lack of evidence is of particular concern in the case of treatment guidelines.

The present article reviews important work that has given rise to current treatment guidelines. While most of these guidelines reveal the lack of evidence available on this subject, can, nevertheless, be concluded that a 6-month treatment regimen similar to that used in patients with pulmonary TB may be sufficient to treat all forms of EPTB, including meningeal disease. The role of steroids and surgery in the treatment of TB affecting different sites is also discussed. Other topics dealt with are the considerations that should be taken into account and the treatment modifications necessary in patients infected with the human immunodeficiency virus.

Key words:
Extrapulmonary tuberculosis
Treatment
Surgery
Steroids

La tuberculosis (TB) puede afectar, por diseminación hematógena, linfática o contigüidad, a cualquier órgano o tejido del organismo. Sin embargo, la forma de presentación pulmonar es la más frecuente y la única epidemiológicamente importante. Esto ha motivado que las publicaciones sobre las diversas localizaciones de la TB extrapulmonar (TBE) hayan sido escasas, y casi siempre realizadas por especialistas de las diferentes presentaciones. Por tal motivo, en la mayoría de los grandes campos de estudio de la TBE se han aceptado recomendaciones similares a las efectuadas para la TB pulmonar, o se han seguido otras con escasa o nula evidencia; aspecto especialmente relevante en lo concerniente al tratamiento.

En el presente artículo se revisan importantes publicaciones que han dado lugar a las actuales recomendaciones sobre el tratamiento, detrás de la mayoría de las cuales resalta la falta de evidencia existente. En cualquier caso, se concluye que un régimen de 6 meses, similar al de la TB pulmonar, puede ser suficiente para tratar todas las formas de TBE, incluida la meníngea. Se discute, igualmente, el papel que los esteroides y la cirugía pueden tener en las diversas localizaciones de la TB, así como las modificaciones y/o consideraciones que deben tenerse en cuenta en los pacientes infectados por el virus de la inmunodeficiencia humana.

Palabras clave:
Tuberculosis extrapulmonar
Tratamiento
Cirugía
Esteroides
Full text is only aviable in PDF
REFERENCES
[1]
A Dannenberg, Tomashefki.
Pathogenesis of pulmonary tuberculosis.
Pulmonary diseases and disorders, pp. 177-323
[2]
Tuberculosis,
[3]
JF Murray, JA Nadel.
Extrapulmonary tuberculosis.
Textbook of respiratory medicine, pp. 878-889
[4]
JA Caminero.
Guía de la tuberculosis para médicos especialistas. Unión Internacional contra la Tuberculosis y Enfermedades Respiratorias (UICTER), UICTER, (2003),
[5]
World Health Organization.
WHO tuberculosis programme: framework for effective tuberculosis control, WHO, (1994),
[6]
JP Narain, YR Lo.
Epidemiology of HIV-TB in Asia.
Indian J Med Res., 120 (2004), pp. 277-289
[7]
JB Mehta, A Dutt, L Harvill, KM Mathews.
Epidemiology of extrapulmonary tuberculosis. A comparative analysis with pre-AIDS era.
Chest, 99 (1991), pp. 1134-1138
[8]
A Kok-Jensen, K Viskum.
Extrapulmonary tuberculosis in Denmark. A review of the incidence, localization and therapy.
Ugeskr Laeger, 156 (1994), pp. 5266-5268
[9]
MC Raviglione, JP Narain, A Kochi.
HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment.
Bull World Health Organ., 70 (1992), pp. 515-526
[10]
JL Calpe, E Chiner, J Marín-Pardo, V Armero, A Calpe.
Evolución de las características epidemiológicas de la tuberculosis en el Área 15 de la Comunidad Valenciana en el período 1987-2001.
Arch Bronconeumol., 41 (2005), pp. 118-124
[11]
RW Sheafer, DS Kim, JP Weiss.
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection.
Medicine (Baltimore)., 70 (1991), pp. 384
[12]
CL Daley, PM Small, GF Schecter.
An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus.
N Engl J Med., 326 (1992), pp. 231-235
[13]
NC Elder.
Extrapulmonary tuberculosis. A review.
Arch Fam Med., 1 (1992), pp. 91-98
[14]
S Álvarez, WR McCabe.
Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals.
Medicine (Baltimore)., 63 (1984), pp. 25-55
[15]
AD Harries.
Tuberculosis and human immunodeficiency virus infection in developing countries.
Lancet, 335 (1990), pp. 387-390
[16]
L Aaron, D Saadoun, I Calatroni, O Launay, N Memain, V Vincent, et al.
Tuberculosis in HIV-infected patients: a comprehensive review.
Clin Microbiol Infect., 10 (2004), pp. 388-398
[17]
Z Fuentes, JA Caminero, M España, T Martín, L Arvelo, L Garrido, et al.
Evolution of the extrapulmonary tuberculosis incidence rates in Venezuela (1992–2001).
Int J Tuberc Lung Dis., 7 (2003), pp. 211
[18]
A Banerjee, AD Harries, FM Salaniponi.
Differences in tuberculosis incidence rates in township and in rural populations in Ntcheu District, Malawi.
Trans R Soc Trop Med Hyg., 93 (1999), pp. 392-393
[19]
A Ilgazli, H Boyaci, I Basyigit, F Yildiz.
Extrapulmonary tuberculosis: clinical and epidemiologic spectrum of 636 cases.
Arch Med Res., 35 (2004), pp. 435-441
[20]
SK Sharma, A Mohan.
Extrapulmonary tuberculosis.
Indian J Med Res., 120 (2004), pp. 316-353
[21]
FL Lado, V Tunez, AL Golpe, MJ Ferreiro, A Cabarco.
Extrapulmonary tuberculosis in our area. Forms of presentation.
An Med Interna., 17 (2000), pp. 637-641
[22]
JA Caminero, Z Fuentes, T Martín, M España, G Istúriz, E Ávila, et al.
A six-month treatment, with medication three times a week in the second phase, for extrapulmonary tuberculosis. Study with 679 cases.
Int J Tuberc Lung Dis., 9 (2005), pp. 890-895
[23]
S Lenk, J Schroeder.
Genitourinary tuberculosis.
Curr Opin Urol., 11 (2001), pp. 93-98
[24]
RS Morehead.
Tuberculosis of the pleura.
South Med J., 91 (1998), pp. 630-636
[25]
B Ozbay, K Uzun.
Extrapulmonary tuberculosis in high prevalence of tuberculosis and low prevalence of HIV.
Clin Chest Med., 23 (2002), pp. 351-354
[26]
FL Lado, E Barrio, E Carballo, A Cabarcos.
Tuberculosis e infección por el virus de la inmunodeficiencia humana: manifestaciones clínicas y rentabilidad de las técnicas diagnósticas según la localización de la enfermedad.
An Med Interna., 17 (2000), pp. 13-18
[27]
MJ Cremades, R Menéndez, M Santos, MA Martínez, D Ferrando.
Características de la tuberculosis en un hospital terciario durante los años 1993–1996. Influencia de la coinfección por el VIH.
Arch Bronconeumol., 34 (1998), pp. 333-338
[28]
A Mohan, SK Sharma.
Epidemiology.
Tuberculosis, pp. 14-29
[29]
SM Hsieh, CC Hung, MY Chen, SC Chang, PR Hsueh, KT Luh, et al.
Clinical features of tuberculosis associated with HIV infection in Taiwan.
J Formos Med Assoc., 95 (1996), pp. 923-928
[30]
V Carcaba, JA Cartón, J Moris, Z García Amorín, M García Clemente, M Rodríguez Junquera, et al.
Tuberculosis e infección VIH. Evaluación de 132 casos.
Rev Clin Esp., 193 (1993), pp. 12-16
[31]
ZA Bukhary, AA Alrajhi.
Extrapulmonary tuberculosis, clinical presentation and outcome.
Saudi Med J., 25 (2004), pp. 881-885
[32]
A Kok-Jensen, K Viskum.
Extrapulmonary tuberculosis in Denmark. A review of the incidence, localization and therapy.
Ugeskr Laeger, 156 (1994), pp. 5266-5268
[33]
M Leal, A Gaafarb, MJ Unzaga, JA Crespo, R Cisterna, F García.
Estudio clinicoepidemiológico de la enfermedad por Mycobacterium kansasii en el área urbana de Bilbao.
Arch Bronconeumol., 41 (2005), pp. 189-196
[34]
S Bouraoui, S Haouet, A Mekni, L El Ouertani, K Bellil, S Bellil, et al.
Extrapulmonary tuberculosis in Tunisia. Report of 830 cases. Experience of the Anatomic Pathology Laboratory of the Rabta Hospital.
Tunis Med., 81 (2003), pp. 529-534
[35]
MA Fernández Jorge, E Alonso Mallo, LA Lobato Delgado, JM Martínez Sánchez.
Tuberculosis extrapulmonar: estudio retrospectivo de 107 casos.
An Med Intern., 12 (1995), pp. 212-215
[36]
DM Epstein, LR Kline, SM Albelda, WT Miller.
Tuberculous pleural effusions.
Chest, 91 (1987), pp. 106-109
[37]
C Escudero Bueno, M García Clemente, B Cuesta Castro.
Cytologic and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle.
Arch Intern Med., 150 (1990), pp. 1190-1194
[38]
JC Hurley, JH Andrew.
Bacteriology and drug susceptibility of tuberculosis at St. Vincent's Hospital, Melbourne, 1962–1991.
Tuber Lung Dis., 74 (1993), pp. 163-166
[39]
L Valdés, A Pose, E San José, JM Martínez-Vázquez.
Tuberculous pleural effusions.
Eur J Intern Med., 14 (2003), pp. 77-88
[40]
JA Caminero.
Tuberculosis pleural.
Med Clin (Barc)., 94 (1990), pp. 384-388
[41]
E García, I Padilla, C Shum.
Mesotelioma, adenosindesaminasa y proteína C reactiva.
Arch Bronconeumol., 41 (2005), pp. 175
[42]
M Salazar, H Quiroz, J Bañales, M Sánchez, H Villareal, et al.
Diagnostic methods of primary tuberculous pleural effusion in a region with high prevalence of tuberculosis.
Rev Invest Clin., 49 (1997), pp. 453-456
[43]
JA Caminero, M Casal, V Ausina, JM Pina, J Sauret.
Diagnóstico de la tuberculosis.
Arch Bronconeumol., 32 (1996), pp. 85-89
[44]
RW Shafer, DS Kim, JP Weiss, JM Quale.
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection.
Medicine (Baltimore)., 70 (1991), pp. 384-397
[45]
A Trajman, EB Neto, MT Belo, EG Teixeira, L Selig, G Ferrari, et al.
Pleural tuberculosis and human immunodeficiency virus co-infection.
Int J Tuberc Lung Dis., 1 (1997), pp. 498-501
[46]
RA Clark, SL Blakley, D Greer, MH Smith, W Brandon, TL Wisniewski.
Hematogenous dissemination of Mycobacterium tuberculosis in patients with AIDS.
Rev Infect Dis., 13 (1991), pp. 1089-1092
[47]
AR Hill, S Premkumar, S Brustein, K Vaidya, S Powell, PW Li, et al.
Disseminated tuberculosis in the acquired immunodeficiency syndrome era.
Am Rev Respir Dis., 144 (1991), pp. 1164-1170
[48]
World Health Organisation.
Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Publication WHO/CDS/TB/ 2003, World Health Organisation, (2003),
[49]
International Union against Tuberculosis and Lung Diseases.
Tuberculosis guide for low-income countries, 5th ed., International against TB and Lung Disease, (2000),
[50]
Canadian Paediatric Society.
Infectious Diseases and Immunisation Committee. Short-course therapy for tuberculosis in infants and children.
CMAJ., 151 (1994), pp. 912-913
[51]
Joint Tuberculosis Committee of the British Thoracic Society.
Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998.
Thorax, 53 (1998), pp. 536-548
[52]
CR Horsburgh Jr, S Feldman, R Ridzon.
Practice guidelines for the treatment of tuberculosis (guidelines from the Infectious Diseases Society of America).
Clin Infect Dis., 31 (2000), pp. 633-639
[53]
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America.
Treatment of tuberculosis.
Am J Respir Crit Care Med., 107 (2003), pp. 603-662
[54]
PR Donald, JF Schoeman, LE van Zyl, JN de Villiers, M Pretorius, P Springer.
Intensive short course chemotherapy in the management of tuberculous meningitis.
Int J Tuberc Lung Dis., 2 (1998), pp. 704-711
[55]
APW Yuen, SHW Wong, CM Tam, SL Chan, WI Wei, SK Lau.
Prospective randomised study of the thrice weekly six month and nine-month chemotherapy for cervical tuberculous lymphadenopathy.
Otolaryngol Head Neck Surg., 116 (1997), pp. 189-192
[56]
British Thoracic Society Research Committee.
Six-months versus nine-months chemotherapy for tuberculosis of lymph nodes: preliminary results.
Respir Med., 86 (1992), pp. 15-19
[57]
IA Campbell, LP Ormerod, PA Friend, R Jenkins, J Prescott.
Six months versus nine months chemotherapy for tuberculosis of lymph nodes: final results.
Respir Med., 87 (1993), pp. 621-623
[58]
Medical Research Council Working Party on Tuberculosis of the Spine.
Five years assessment of controlled trials of short-course chemotherapy regimen of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery.
Int Orthop., 23 (1999), pp. 73-81
[59]
Medical Research Council Working Party on Tuberculosis of the Spine.
A controlled trial of six-month and nine-month regimen of chemotherapy in patients undergoing radical surgery for tuberculosis of the spine in Hong Kong.
Tubercle., 67 (1986), pp. 243-259
[60]
V Skutil, J Varsa, M Obsitnik.
Six-month chemotherapy for urogenital tuberculosis.
Eur Urol., 11 (1985), pp. 170-176
[61]
RF Jacobs, P Sunakorn, T Chotpitavasunonah, S Pope, K Kelleher.
Intensive short course chemotherapy for tuberculous meningitis.
Pediatr Infect Dis J., 11 (1992), pp. 194-198
[62]
JH van Loenhout-Rooyackers, A Keyser, RJF Laheij, ALM Verbeek, JWM van der Mer.
Tuberculosis meningitis: is a 6–month treatment regimen sufficient?.
Int J Tuberc Lung Dis., 5 (2001), pp. 1028-1035
[63]
DL Cohn, BJ Catlin, KL Peterson, FN Judson, JA Sbarbaro.
A 62– dose, 6–month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
Ann Intern Med., 112 (1990), pp. 407-415
[64]
S Lenk, J Schroeder.
Genitourinary tuberculosis.
Curr Opin Urol., 11 (2001), pp. 93-98
[65]
NO Fowler.
Tuberculous pericarditis.
JAMA., 266 (1991), pp. 99-103
[66]
I Galarza, C Canete, A Granados, R Estopa, F Manresa.
Randomised trial of corticosteroids in the treatment of tuberculous pleurisy.
Thorax, 50 (1995), pp. 1305-1307
[67]
AK Dutt, D Moers, WW Stead.
Short-course chemotherapy for pleural tuberculosis. Nine years' experience in routine treatment service.
Chest, 90 (1986), pp. 112-116
[68]
N Machado, CS Grant, E Scrimgeour.
Abdominal tuberculosis experience of a university hospital in Oman.
Acta Trop., 80 (2001), pp. 187-190
[69]
MS Moon, YW Moon, JL Moon, SS Kim, DH Sun.
Conservative treatment of tuberculosis of the lumbar and lumbosacral spine.
Clin Orthop., 398 (2002), pp. 40-49
[70]
A Mert, M Bilir, F Tabak, R Ozaras, R Ozturk.
Miliary tuberculosis: clinical manifestations, diagnosis and outcome in 38 adults.
Respirology, 6 (2001), pp. 217-224
[71]
AK Dutt, D Moers, WW Stead.
Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience.
Ann Intern Med., 104 (1986), pp. 7-12
[72]
AK Dutt, WW Stead.
Treatment of extrapulmonary tuberculosis.
Semin Respir Infect., 4 (1989), pp. 225-231
[73]
RE Chaisson, HC Clermont, EA Holt, M Cantave, MP Johnson, J Atkinson, et al.
Six month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection.
Am J Respir Crit Care Med., 154 (1996), pp. 1034-1038
[74]
MS Jawahar, S Sivasubramanian, VK Vijayan, CV Ramakrishnan, CN Paramasivan, V Selvakumar, et al.
Short course chemotherapy for tuberculous lymphadenitis in children.
BMJ., 301 (1990), pp. 359-362
[75]
WL Cheung, KF Siu, A Ng.
Six-month combination chemotherapy for cervical tuberculous lymphadenitis.
J R Coll Surg Edinb., 35 (1992), pp. 293-295
[76]
JH van Loenhout-Rooyackers, A Keyser, RJ Laheij, AL Verbeek, JW van der Meer.
Tuberculous meningitis: is a 6–month treatment regimen sufficient?.
Int J Tuberc Lung Dis., 5 (2001), pp. 1028-1035
[77]
KC Mohanty, S Bendre.
Changing trends in management of HIV and TB.
J Indian Med Assoc., 101 (2003), pp. 186-188
[78]
JA Caminero.
Is the DOTS strategy sufficient to achieve tuberculosis control in low-and middle-income countries? 2. Need for interventions among private physicians, medical specialists and scientific societies.
Int J Tuberc Lung Dis., 7 (2003), pp. 623-630
[79]
CA Lobo, E Pérez.
Control y supervisión del enfermo tuberculoso.
Arch Bronconeumol., 37 (2001), pp. 43-47
[80]
R Vidal, R Rey, A Espinar, P de March, C Melero, JM Pina, et al.
Tratamiento y retratamiento de la tuberculosis (normativas SEPAR).
Arch Bronconeumol., 32 (1996), pp. 463-474
[81]
GE Thwaites, DB Ngayen, HD Nguyen.
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.
N Engl J Med., 351 (2004), pp. 1741-1751
[82]
NI Girgis, Z Farid, ME Kilpatrick, Y Sultan, IA Mikhail.
Dexamethasone adjunctive treatment for tuberculous meningitis.
Pediatr Infect Dis J., 10 (1991), pp. 179-183
[83]
JI Strang, HH Kakaza, DG Gibson, BW Allen, DA Mitchison.
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei.
Lancet, 2 (1988), pp. 759-764
[84]
JI Strang, HH Kakaza, DG Gibson, DJ Girling, AJ Nunn, W Fox.
Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei.
Lancet, 2 (1987), pp. 1418-1442
[85]
C Wyser, G Walzl, JP Smedema, F Swart, M van Schalkwyk, BW van de Wal.
Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo-controlled, randomized study.
Chest, 110 (1996), pp. 333-338
[86]
CH Lee, WJ Wang, RS Lan, YH Tsai, YC Chiang.
Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo controlled, randomized study.
Chest, 94 (1988), pp. 1256-1259
[87]
PT Matchaba, J Volmink.
Steroids for treating tuberculous pleurisy.
Cochrane Database Syst Rev., 2 (2000),
[88]
E Soriano, J Mallolas, JM Gatell, X Latorre, JM Miro.
Characteristics of tuberculosis in HIV-infected patients: a case-control study.
AIDS., 2 (1988), pp. 429-432
[89]
CP Chiu, WW Wong, B Kuo, TM Tiao, CP Fung, CY Liu.
Clinical analysis of Mycobacterium tuberculosis infection in patients with acquired immunodeficiency syndrome.
J Microbiol Immunol Infect., 32 (1999), pp. 250-256
[90]
SM Hsieh, CC Hung, MY Chen, SC Chang, PR Hsueh, et al.
Clinical features of tuberculosis associated with HIV infection in Taiwan.
J Formos Med Assoc., 95 (1996), pp. 923-928
[91]
JC Vázquez, E Sada, E Rivera, O Narváez, MA Salazar.
Tuberculosis asociada a infección VIH.
Rev Invest Clin., 46 (1994), pp. 473-477
[92]
H Nagai.
HIV infection and tuberculosis.
Kekkaku., 78 (2003), pp. 45-49
[93]
HJ Chum, RJ O'Brien, TM Chonde, P Graf, HL Rieder.
An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991–1993.
AIDS., 10 (1996), pp. 299-309
[94]
K Noertjojo, CM Tam, SL Chan, MM Chan-Yeung.
Extra pulmonary and pulmonary tuberculosis in Hong Kong.
Int J Tuberc Lung Dis., 6 (2002), pp. 879-886
[95]
JN Kitinya, C Richter, R Perenboom, H Chande, IM Mtoni.
Influence of HIV status on pathological changes in tuberculous pleuritis.
Tuber Lung Dis., 75 (1994), pp. 195-198
[96]
JB Marshall.
Tuberculosis of the gastrointestinal tract and peritoneum.
Am J Gastroenterol., 88 (1993), pp. 989-999
[97]
DA Watters.
Surgery for tuberculosis before and after human immunodeficiency virus infection: a tropical perspective.
Br J Surg., 84 (1997), pp. 8-14
[98]
VK Yechoor, WX Shandera, P Rodríguez, TR Cate.
Tuberculous meningitis among adults with and without HIV infection: experience in an urban public hospital.
Arch Intern Med., 156 (1996), pp. 1710-1716
[99]
M Narita, D Ashkin, ES Hollender, AE Pitchenik.
Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.
Am J Respir Crit Care Med., 158 (1998), pp. 157-161
[100]
KA Wendel, KS Alwood, R Gachuhi, RE Chaisson, WR Bishai, TR Sterling.
Paradoxical worsening of tuberculosis in HIV-infected persons.
Chest, 120 (2001), pp. 193-197
[101]
M Rocha, S Pereira, L Ferreira, H Barros.
The role of adherence in tuberculosis HIV-positive patients treated in ambulatory regimen.
Eur Respir J., 21 (2003), pp. 785-788
[102]
NN Naing, C D'Este, AR Isa, R Salleh, N Bakar, MR Mahmod.
Factors contributing to poor compliance with anti-TB treatment among tuberculosis patients.
Southeast Asian J Trop Med Public Health, 32 (2001), pp. 369-382
[103]
S Tansuphasawadikul, DM Poprawski, P Pitisuttithum, B Phonrat.
Nonadherence in tuberculosis treatment among HIV patients attending Bamrasnaradura Hospital, Nonthaburi.
J Med Assoc Thai., 81 (1998), pp. 964-969
[104]
F Pulido, JM Sánchez, R Rubio, J González, JR Costa.
Factores predictores de no cumplimiento del tratamiento antituberculoso en pacientes afectados por el virus de la inmunodeficiencia humana.
Rev Clin Esp., 197 (1997), pp. 163-166
[105]
AD Harries, DS Nyangulu, C Kang'ombe, D Ndalama, JR Glynn.
Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba Hospital, Malawi.
Trans R Soc Trop Med Hyg., 92 (1998), pp. 343-347
[106]
A Pablos-Méndez, CA Knirsch, RG Barr, BH Lerner, TR Frieden.
Nonadherence in tuberculosis treatment: predictors and consequences in New York City.
Am J Med., 102 (1997), pp. 164-170
[107]
M Cator, P Brassard, S Ducic, K Culman.
Factors related to noncompliance with active tuberculosis treatment in Montreal 19921995.
Can J Public Health, 93 (2002), pp. 92-97
[108]
JA Caminero, JM Pavón, F Rodríguez de Castro, F Díaz, G Julia, JA Cayla, et al.
Evaluation of a directly observed six months fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance.
Thorax, 51 (1996), pp. 1130-1133
[109]
AI el-Sony, AH Khamis, DA Enarson, O Baraka, SA Mustafa, G Bjune.
Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection.
Int J Tuberc Lung Dis., 6 (2002), pp. 1058-1066
[110]
A Marco, JA Caylá, M Serra, R Pedro, C Sanrama, R Guerrero, et al.
Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of Prisoners.
Eur Respir J., 12 (1998), pp. 967-971
[111]
JG Freixinet, JJ Rivas, F Rodríguez de Castro, JA Caminero, P Rodríguez, M Serra, et al.
Role of surgery in pulmonary tuberculosis.
Med Sci Monit., 8 (2002), pp. 782-786
[112]
YC Lee, SP Luh, RM Wu, TP Lin, KT Luh.
Current role of surgery in the management of pleuropulmonary tuberculosis.
J Formos Med Assoc., 93 (1994), pp. 836-841
[113]
M Bajpai, L Nambhirajan, S Dave, AK Gupta.
Surgery in tuberculosis.
Indian J Pediatr., 67 (2000), pp. 53-57
[114]
N Lal, V Soto-Wright.
Peritoneal tuberculosis: diagnostic options.
Infect Dis Obstet Gynecol., 7 (1999), pp. 244-247
[115]
VK Kapoor.
Abdominal tuberculosis.
Postgrad Med J., 74 (1998), pp. 459-467
[116]
M Ciurea, D Ion, S Ionescu, MR Tica.
Intestinal tuberculosis cause of acute surgical abdomen.
Chirurgia (Bucur)., 96 (2001), pp. 605-608
[117]
S Yriberry, Z Cervera, C Soriano, O Frisancho, A Machado, E Zumaeta.
Tuberculosis digestiva en el Hospital Edgardo Rebagliati Martin: estudio durante un período de 5 años (1993–1998).
Rev Gastroenterol Peru., 18 (1998), pp. 238-249
[118]
TP Mochalova, IY Starikov.
Reconstructive surgery for treatment of urogenital tuberculosis: 30 years of observation.
World J Surg., 21 (1997), pp. 511-515
[119]
NN Chowdhury.
Overview of tuberculosis of the female genital tract.
J Indian Med Assoc., 94 (1996), pp. 345-346
Copyright © 2006. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?